HPV-FASTER: broadening the scope for prevention of HPV-related cancer

F Xavier Bosch; Claudia Robles; Mireia Díaz; Marc Arbyn; Iacopo Baussano; Christine Clavel; Guglielmo Ronco; Joakim Dillner; Matti Lehtinen; Karl-Ulrich Petry; Mario Poljak; Susanne K Kjaer; Chris J L M Meijer; Suzanne M Garland; Jorge Salmerón; Xavier Castellsagué; Laia Bruni; Silvia de Sanjosé; Jack Cuzick

doi:10.1038/nrclinonc.2015.146

HPV-FASTER: broadening the scope for prevention of HPV-related cancer

F Xavier Bosch, Claudia Robles, Mireia Díaz, Marc Arbyn, Iacopo Baussano, Christine Clavel, Guglielmo Ronco, Joakim Dillner, Matti Lehtinen, Karl-Ulrich Petry, Mario Poljak, Susanne K Kjaer, Chris J L M Meijer, Suzanne M Garland, Jorge Salmerón, Xavier Castellsagué, Laia Bruni, Silvia de Sanjosé, Jack Cuzick

Department of Clinical Medicine

109 Citations (Scopus)

Abstract

Human papillomavirus (HPV)-related screening technologies and HPV vaccination offer enormous potential for cancer prevention, notably prevention of cervical cancer. The effectiveness of these approaches is, however, suboptimal owing to limited implementation of screening programmes and restricted indications for HPV vaccination. Trials of HPV vaccination in women aged up to 55 years have shown almost 90% protection from cervical precancer caused by HPV16/18 among HPV16/18-DNA-negative women. We propose extending routine vaccination programmes to women of up to 30 years of age (and to the 45-50-year age groups in some settings), paired with at least one HPV-screening test at age 30 years or older. Expanding the indications for HPV vaccination and much greater use of HPV testing in screening programmes has the potential to accelerate the decline in cervical cancer incidence. Such a combined protocol would represent an attractive approach for many health-care systems, in particular, countries in Central and Eastern Europe, Latin America, Asia, and some more-developed parts of Africa. The role of vaccination in women aged >30 years and the optimal number of HPV-screening tests required in vaccinated women remain important research issues. Cost-effectiveness models will help determine the optimal combination of HPV vaccination and screening in public health programmes, and to estimate the effects of such approaches in different populations.

Original language	English
Journal	Nature Reviews Clinical Oncology
Volume	13
Issue number	2
Pages (from-to)	119-32
Number of pages	14
ISSN	1759-4774
DOIs	https://doi.org/10.1038/nrclinonc.2015.146
Publication status	Published - 1 Feb 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrclinonc.2015.146

Cite this

Bosch, F. X., Robles, C., Díaz, M., Arbyn, M., Baussano, I., Clavel, C., Ronco, G., Dillner, J., Lehtinen, M., Petry, K.-U., Poljak, M., Kjaer, S. K., Meijer, C. J. L. M., Garland, S. M., Salmerón, J., Castellsagué, X., Bruni, L., de Sanjosé, S., & Cuzick, J. (2016). HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nature Reviews Clinical Oncology, 13(2), 119-32. https://doi.org/10.1038/nrclinonc.2015.146

Bosch, FX, Robles, C, Díaz, M, Arbyn, M, Baussano, I, Clavel, C, Ronco, G, Dillner, J, Lehtinen, M, Petry, K-U, Poljak, M, Kjaer, SK, Meijer, CJLM, Garland, SM, Salmerón, J, Castellsagué, X, Bruni, L, de Sanjosé, S & Cuzick, J 2016, 'HPV-FASTER: broadening the scope for prevention of HPV-related cancer', Nature Reviews Clinical Oncology, vol. 13, no. 2, pp. 119-32. https://doi.org/10.1038/nrclinonc.2015.146

@article{6cd31c37894f4790b0ab69c4d705ede1,

title = "HPV-FASTER: broadening the scope for prevention of HPV-related cancer",

abstract = "Human papillomavirus (HPV)-related screening technologies and HPV vaccination offer enormous potential for cancer prevention, notably prevention of cervical cancer. The effectiveness of these approaches is, however, suboptimal owing to limited implementation of screening programmes and restricted indications for HPV vaccination. Trials of HPV vaccination in women aged up to 55 years have shown almost 90% protection from cervical precancer caused by HPV16/18 among HPV16/18-DNA-negative women. We propose extending routine vaccination programmes to women of up to 30 years of age (and to the 45-50-year age groups in some settings), paired with at least one HPV-screening test at age 30 years or older. Expanding the indications for HPV vaccination and much greater use of HPV testing in screening programmes has the potential to accelerate the decline in cervical cancer incidence. Such a combined protocol would represent an attractive approach for many health-care systems, in particular, countries in Central and Eastern Europe, Latin America, Asia, and some more-developed parts of Africa. The role of vaccination in women aged >30 years and the optimal number of HPV-screening tests required in vaccinated women remain important research issues. Cost-effectiveness models will help determine the optimal combination of HPV vaccination and screening in public health programmes, and to estimate the effects of such approaches in different populations.",

author = "Bosch, {F Xavier} and Claudia Robles and Mireia D{\'i}az and Marc Arbyn and Iacopo Baussano and Christine Clavel and Guglielmo Ronco and Joakim Dillner and Matti Lehtinen and Karl-Ulrich Petry and Mario Poljak and Kjaer, {Susanne K} and Meijer, {Chris J L M} and Garland, {Suzanne M} and Jorge Salmer{\'o}n and Xavier Castellsagu{\'e} and Laia Bruni and {de Sanjos{\'e}}, Silvia and Jack Cuzick",

year = "2016",

month = feb,

day = "1",

doi = "10.1038/nrclinonc.2015.146",

language = "English",

volume = "13",

pages = "119--32",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "nature publishing group",

number = "2",

}

TY - JOUR

T1 - HPV-FASTER

T2 - broadening the scope for prevention of HPV-related cancer

AU - Bosch, F Xavier

AU - Robles, Claudia

AU - Díaz, Mireia

AU - Arbyn, Marc

AU - Baussano, Iacopo

AU - Clavel, Christine

AU - Ronco, Guglielmo

AU - Dillner, Joakim

AU - Lehtinen, Matti

AU - Petry, Karl-Ulrich

AU - Poljak, Mario

AU - Kjaer, Susanne K

AU - Meijer, Chris J L M

AU - Garland, Suzanne M

AU - Salmerón, Jorge

AU - Castellsagué, Xavier

AU - Bruni, Laia

AU - de Sanjosé, Silvia

AU - Cuzick, Jack

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Human papillomavirus (HPV)-related screening technologies and HPV vaccination offer enormous potential for cancer prevention, notably prevention of cervical cancer. The effectiveness of these approaches is, however, suboptimal owing to limited implementation of screening programmes and restricted indications for HPV vaccination. Trials of HPV vaccination in women aged up to 55 years have shown almost 90% protection from cervical precancer caused by HPV16/18 among HPV16/18-DNA-negative women. We propose extending routine vaccination programmes to women of up to 30 years of age (and to the 45-50-year age groups in some settings), paired with at least one HPV-screening test at age 30 years or older. Expanding the indications for HPV vaccination and much greater use of HPV testing in screening programmes has the potential to accelerate the decline in cervical cancer incidence. Such a combined protocol would represent an attractive approach for many health-care systems, in particular, countries in Central and Eastern Europe, Latin America, Asia, and some more-developed parts of Africa. The role of vaccination in women aged >30 years and the optimal number of HPV-screening tests required in vaccinated women remain important research issues. Cost-effectiveness models will help determine the optimal combination of HPV vaccination and screening in public health programmes, and to estimate the effects of such approaches in different populations.

AB - Human papillomavirus (HPV)-related screening technologies and HPV vaccination offer enormous potential for cancer prevention, notably prevention of cervical cancer. The effectiveness of these approaches is, however, suboptimal owing to limited implementation of screening programmes and restricted indications for HPV vaccination. Trials of HPV vaccination in women aged up to 55 years have shown almost 90% protection from cervical precancer caused by HPV16/18 among HPV16/18-DNA-negative women. We propose extending routine vaccination programmes to women of up to 30 years of age (and to the 45-50-year age groups in some settings), paired with at least one HPV-screening test at age 30 years or older. Expanding the indications for HPV vaccination and much greater use of HPV testing in screening programmes has the potential to accelerate the decline in cervical cancer incidence. Such a combined protocol would represent an attractive approach for many health-care systems, in particular, countries in Central and Eastern Europe, Latin America, Asia, and some more-developed parts of Africa. The role of vaccination in women aged >30 years and the optimal number of HPV-screening tests required in vaccinated women remain important research issues. Cost-effectiveness models will help determine the optimal combination of HPV vaccination and screening in public health programmes, and to estimate the effects of such approaches in different populations.

U2 - 10.1038/nrclinonc.2015.146

DO - 10.1038/nrclinonc.2015.146

M3 - Journal article

C2 - 26323382

SN - 1759-4774

VL - 13

SP - 119

EP - 132

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 2

ER -

HPV-FASTER: broadening the scope for prevention of HPV-related cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this